|
|
|
|
|
HIGHLIGHTS FROM THE 2023 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
| Bladder Cancer: Non-Invasive
|
|
| Progression-Free Survival as Surrogate Endpoint in High-Risk Non-Muscle Invasive Bladder Cancer Studies: Results from a Machine Learning-Based Analysis of a Large Multi-Institutional Database
|
| Michele Marchioni, MD, Ph.D. |
| Michele Marchioni presents a study evaluating progression-free survival as a surrogate outcome of overall survival in a cohort of high-risk non-muscle invasive bladder cancer patients, using results from a machine learning-based analysis of a large multi-institutional database. |
|
|
|
|
|
| Sequential Intravesical Gemcitabine and Docetaxel for Treatment-Naive and Previously Treated Intermediate-Risk Non-Muscle Invasive Bladder Cancer |
| Ian McElree |
| Ian McElree presents his group’s work evaluating sequential intravesical gemcitabine and docetaxel for both treatment-naive and previously treated intermediate-risk non-muscle invasive bladder cancer patients. Gem/Doce was an effective and well-tolerated adjuvant therapy in a heterogeneous population of patients with intermediate-risk NMIBC. Based on these results, further prospective evaluation is needed. |
|
|
|
|
|
| The Role of Flexible Blue Light Cystoscopy in Surveillance of Non-Muscle Invasive Bladder Cancer. Results From a Nordic Registry
|
| Karsten Zieger, MD, Ph.D.
|
| Karsten Zieger presented the results of an analysis from the Nordic registry evaluating the role of flexible blue light cystoscopy in the surveillance of non-muscle invasive bladder cancer. This study aimed to further evaluate the performance of blue light flexible cystoscopy (BLFC) in the surveillance setting.
|
|
|
|
|
|
| Comparison of Intravesical Therapy and Surgery as Treatment Options for Recurrent Bladder Cancer (CISTO): Collection of Patient-Reported Outcomes
|
| John Gore, MD, MS
|
| Based on the current high rate of survey completion, the CISTO Study will be powered to compare outcomes across a variety of domains, including QoL, urinary function, and anxiety. The low completion rate of questions relating to sexual function makes it unlikely that this study will yield valid and/or generalizable results in this specific domain.
|
|
|
|
|
|
|
|
|
|
|
| CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG) |
| Roger Li, MD |
| Roger Li presents the results of CORE1, a phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guerin. The combination of CG0070 and pembrolizumab appears to be highly active in BCG-unresponsive NMIBC based on preliminary results of the CORE-001 study. |
|
|
|
|
|
| Transurethral En Bloc Resection versus Standard Resection of Bladder Tumor: A Multi-Center Randomized Trial (EB-StaR Study) |
| Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery) |
| Jeremy Teoh presents the results of the EB-StaR Study, a multicenter randomized trial of transurethral en bloc versus standard resection of bladder tumors. The EB-StaR study is a randomized, multicenter phase 3 trial comparing en bloc versus standard resection of bladder tumors. |
|
|
|
|
|
| Bladder Sparing Treatment in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: An Analysis of Long-Term Survival Outcomes
|
| Wei Shen Tan, MD, Ph.D.
|
| Wei Shen Tan presented the results of an analysis of long-term survival outcomes of patients with BCG unresponsive, non-muscle invasive bladder cancer managed with bladder-sparing treatments. These results may help in counseling patients and allay fears in select BCG unresponsive patients who are interested in a trial of bladder-sparing treatment. |
|
|
|
|
|
| Deep Learning Algorithms for Multi-Region Bladder Cancer Segmentation
|
| Seyedbehzad Jazayeri, MD
|
| Seyedbehzad Jazayeri gave a presentation regarding deep learning models that use convolutional neural networks (CNN). CNNs employ advanced and quantitative image features inside MRIs to detect the occurrence of muscle invasion. Dr. Jazayeri and colleagues specifically sought to evaluate mpMRI as an algorithm for the automatic detection of bladder tumors, given that prior work has demonstrated their feasibility for fully automated and high-accuracy image segmentation.
|
|
|
|
|
|
| A Transformer-Augmented Deep Learning Algorithm, CystoNet-T, for Improved Cystoscopic Bladder Cancer Detection
|
| Eugene Shkolyar, MD
|
| Eugene Shkoylar and his team shared a presentation on their novel deep learning algorithm, CystoNet-T. Each year, nearly 2.2 million cystoscopies are performed in the United States and Europe in the effort against bladder cancer. To minimize the recurrence of tumors, adequate identification of a lesion is crucial to the treatment a physician provides as the ability identify the extent of a tumor can help with stratifying risk, diagnosis, and selecting appropriate treatment options.
|
|
|
|
|
|
 |
